SARS-CoV-2 Antigen Rapid Test
Providing an aid in early diagnosis of individuals who are suspected of COVID-19 by their healthcare provider and who are asymptomatic.
Providing an aid in early diagnosis of individuals who are suspected of COVID-19 by their healthcare provider and who are asymptomatic.
Apr. 9, 2021 – ACON, oneof the professional in-vitro diagnostic products manufacturers, announced today that its Flowflex SARS-CoV-2 Antigen Rapid Test has been approved for Self-testing use in France and Denmark! Previously, Flowflex SARS-CoV-2 Antigen Rapid Test was granted for Self-testing (Laypersons) use in Germany, Netherlands, Austria and Czech.
ACON Flowflex SARS-CoV-2 Antigen Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection the nucleocapsid protein antigen from SARS-CoV-2 in nasal, saliva and nasopharyngeal swab specimens, it has a high sensitivity and specificity. The SARS-CoV-2 Antigen Rapid Test can also tests pecimens from asymptomatic individuals.
• Nasal, Saliva and Nasopharyngeal swab specimens
• Results in15 minutes
• Excellent performance compared to molecular methods
• Room temperature storage
To fight against COVID-19 epidemic, ACON has developed a full range of COVID-19 testing products including:
• Antigen Rapid Test (Nasal, Saliva, Nasopharyngeal)
• Antibody IgG/IgM Rapid Test
• FIA Antigen Test (Fluorescence ImmunoAssay)
• EIA IgG/EIA IgM
• PCR reagent & PCR analyzer
• Nucleic Extraction Reagent & Instrument
• Neutralizing Antibody (under development)